CardioComm Solutions, Inc.

PRESS RELEASE

FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG

March 8, 2012

CardioComm Solutions Completes Meeting With Visiting Japanese Medical Technology Delegates in Toronto.

Invited by Ontario's Ministry of Economic Development and Innovation and the Canadian Trade Commissioner Service, these meeting provided an opportunity for potential collaboration on innovation and commercialization of leading edge medical imaging technologies.

TORONTO, ONTARIO – CardioComm Solutions, Inc. (CardioComm Solutions) (TSX VENTURE:EKG) was identified as a company of interest to participate in a one day exchange (March 7, 2012) of information and ideas with a visiting Japanese medical technology delegation sponsored by the Ontario's Ministry of Economic Development and Innovation, in partnership with the Canadian Trade Commissioner Service. The objectives of the mission were to promote partnership in innovation, R&D, trade and investment in the area of medical imaging between Canada and Japan.

The one-on-one meetings between CardioComm Solutions and the visiting Japanese companies explored areas of collaboration which could lead to new commercialization opportunities for CardioComm Solutions' bio-monitoring technologies. Given the confidential nature of the meetings and to respect the wishes of the delegation and the Canadian Trade Commissioner Service, the participating organizations from the Japanese delegation will not be disclosed at this date.

CardioComm Solutions is a medical software engineering company specializing in the management of electrocardiograms ("EKGs"), one of the most common diagnostic tests performed. Over the past three years the company has successfully launched solutions that enable the receipt, review and interpretation of EKGs through the use of newer medical devices and communication portals over internet and cellular based technologies. Their EKG management solutions can now service both medical and consumer markets internationally. "Our Global EKG Management System (GEMS) is comprised of two technologies. The first enables the capture and importation of EKG recordings from FDA cleared devices such as the HeartCheck™ PEN, Mobile Cardiac Telemetry Devices ("MCT"), 12 lead EKG machines and cardiac event loop recorders ("ELRS"). Our second proprietary technology is an EKG "viewer" that forms the core of our family of products allowing the EKG wave form to be acquired, reviewed, interpreted and saved, thereby enabling medical professionals to make diagnoses for cardiac arrhythmias. Our EKG SDK viewer is a technology of specific interest to our larger clients as it can be integrated to their own proprietary workflow systems without GEMS™," said Etienne Grima, CEO of CardioComm Solutions.

"Discussions with the visiting delegates highlighted the importance of having access to ready-to-market and proven medical solutions. The Japanese market is active in searching out technologies such as ours to service their growing In-Hospital, Point of Care and Home Monitoring needs. With over 200 million citizens, the consumer market importance also cannot be understated. Follow up discussions are planned as well as the potential for a CardioComm Solutions visit to Japan in 2012", added Grima.

"We were very pleased to have been asked to attend the closed door meetings and to learn more about Japanese advanced technologies. The meetings also allowed us to share our plans for leveraging our history of performance in the health care market as we take first steps towards integrating with new consumer EKG and other bio-sign monitoring devices under the GEMSTM 4.0 software platform. This event presented an excellent opportunity for access into the Japanese market, a medical device market worth approximately $32 billion," said Simi Grosman, member of the board of directors for CardioComm Solutions.

About CardioComm Solutions

CardioComm Solution's patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. CardioComm

Solutions also is cleared by the FDA for the sales of a consumer based HeartCheck™ PEN handheld EKG device and home version of its proprietary GEMS™ Home software. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
egrima@cardiocommsolutions.com
www.cardiocommsolutions.com

Forward-looking statements

This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release